Development asset linked to MAIA Biotechnology in public FDA and regional records.
biotech · Non-Small Cell Lung Cancer · Pneumococcal Vaccines · MAIA
MAIA Biotechnology
MAIA Biotechnology drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
honolulu, USA HQ
2013 Founded
5 Employees
Public company Type
MAIA · NYSE Ticker
Company details
- Status
- Public
- HQ
- honolulu, USA
- Founded
- 2013
- Employees
- 5
- Programs
- 8
- Drugs
- 19
- Patents
- 10
MAIA Biotechnology pipeline
Portfolio lens on 19 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
MAIA Biotechnology drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
cemiplimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in MAIA Biotechnology's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
daptomycin
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
etrasimod
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in MAIA Biotechnology's portfolio. Molecular target: Sphingosine 1-phosphate receptor 1.
- Target
- Sphingosine 1-phosphate receptor 1
- Mechanism
- Sphingosine 1-phosphate receptor Edg-6 modulator
-
US regulatory status: approved. Molecular target: Sphingosine 1-phosphate receptor 1.
- Target
- Sphingosine 1-phosphate receptor 1
- Mechanism
- Sphingosine 1-phosphate receptor Edg-6 modulator
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to MAIA Biotechnology in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Thyroid hormone receptor.
- Target
- Thyroid hormone receptor
- Mechanism
- Thyroid hormone receptor agonist
-
Development asset linked to MAIA Biotechnology in public FDA and regional records.
-
Development asset linked to MAIA Biotechnology in public FDA and regional records.
-
Development asset linked to MAIA Biotechnology in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cholecystokinin receptor type A.
- Target
- Cholecystokinin receptor type A
- Mechanism
- Cholecystokinin A receptor agonist
-
sodium benzoate
Alimentary tract and metabolism (A16)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to MAIA Biotechnology in public FDA and regional records.
-
Development asset linked to MAIA Biotechnology in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to MAIA Biotechnology in public FDA and regional records.
-
Development asset linked to MAIA Biotechnology in public FDA and regional records. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor